Key Takeaways
- • Axel Ekros, an analyst at Stockholm-based stock-picking boutique Protean Funds Scandinavia, supports the portfolio managers of Protean Small Cap, Protean Aktiesparfond Norden and Protean Select, and actively contributes investment views on portfolio decisions despite his analyst title.
- • Ekros's path ran from the Swedish national rowing team through corporate finance, Adrigo Small & Midcap L/S, and a high-yield role at East Capital's crossover credit strategy, giving him both equity and creditor perspectives.
- • His core risk philosophy centers on avoiding positions where a loss could materially impact the portfolio, broader diversification across positions, and recognizing that entry price is critical to future returns.
- • Ekros follows more than 70 companies at Protean, with particular difficulty in small caps and spin-offs that lack sell-side coverage, where investors must rely on their own estimates.
- • He argues that investment success depends as much on temperament as technical skill, and that active fundamental managers may benefit from passive investing's growth and from consolidation among larger fund companies.
Summary
Axel Ekros, an analyst at Protean Funds Scandinavia, is a Nordic equities stock picker whose route into investing began with a book rather than a formal finance track. According to the interview, his parents introduced him to monthly savings in equity funds, but the defining moment came during a training camp with the Swedish national rowing team in the Czech Republic, where he read Joel Greenblatt's *You Can Be a Stock Market Genius*. After his rowing career ended, he moved into finance through a corporate finance internship, then joined Staffan Östlin in assisting with Adrigo Small & Midcap L/S and worked as a high-yield analyst within the East Capital group supporting a crossover credit strategy.
At Protean, Ekros supports the portfolio managers of Protean Small Cap, Protean Aktiesparfond Norden and Protean Select. He describes contributing views on how the firm should act in the market despite retaining the analyst title. He reports that his thinking has shifted toward risk management, namely avoiding positions where a loss could materially affect the portfolio, holding more positions, and weighing both possible and probable outcomes. He also highlights entry price as a major driver of future returns. His credit experience reinforced downside evaluation and sector-specific risk identification, and he argues that each sector has its own key risks and KPIs that must be checked before judging a company's prospects.
Ekros frames his investment discipline partly through elite rowing, which he says instilled tolerance for discomfort and resilience against adverse positions. He cautions that investors who entered the industry after the 2010s have largely not operated in persistently high-rate or prolonged recession environments, and that the past decade's tailwinds can mask how markets function when capital has a cost. Protean follows more than 70 companies, and Ekros says the numbers are the easier part of the job; the harder work is meeting management and deciding whether to buy, sell or do nothing. The challenge is more acute in small caps and spin-offs with limited sell-side coverage, where, he notes, shares can fall even as a company executes to plan.
Working alongside Protean co-founders Pontus Dackmo and Carl Gustafsson and portfolio manager Richard Bråse, Ekros concludes that temperament matters as much as analytical ability. He argues that identifying a cheap asset is insufficient without understanding whether the discount reflects behavioral or structural causes. Looking at Stockholm's investment community, he sees a strong pipeline of young talent and room for smaller, specialized managers as larger fund companies become more bureaucratic, and he believes growing passive investing creates better conditions for active, fundamental-driven funds to generate alpha.
At Protean, Ekros supports the portfolio managers of Protean Small Cap, Protean Aktiesparfond Norden and Protean Select. He describes contributing views on how the firm should act in the market despite retaining the analyst title. He reports that his thinking has shifted toward risk management, namely avoiding positions where a loss could materially affect the portfolio, holding more positions, and weighing both possible and probable outcomes. He also highlights entry price as a major driver of future returns. His credit experience reinforced downside evaluation and sector-specific risk identification, and he argues that each sector has its own key risks and KPIs that must be checked before judging a company's prospects.
Ekros frames his investment discipline partly through elite rowing, which he says instilled tolerance for discomfort and resilience against adverse positions. He cautions that investors who entered the industry after the 2010s have largely not operated in persistently high-rate or prolonged recession environments, and that the past decade's tailwinds can mask how markets function when capital has a cost. Protean follows more than 70 companies, and Ekros says the numbers are the easier part of the job; the harder work is meeting management and deciding whether to buy, sell or do nothing. The challenge is more acute in small caps and spin-offs with limited sell-side coverage, where, he notes, shares can fall even as a company executes to plan.
Working alongside Protean co-founders Pontus Dackmo and Carl Gustafsson and portfolio manager Richard Bråse, Ekros concludes that temperament matters as much as analytical ability. He argues that identifying a cheap asset is insufficient without understanding whether the discount reflects behavioral or structural causes. Looking at Stockholm's investment community, he sees a strong pipeline of young talent and room for smaller, specialized managers as larger fund companies become more bureaucratic, and he believes growing passive investing creates better conditions for active, fundamental-driven funds to generate alpha.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.